Clinical Oncology
Volume 22, Issue 3 , Pages 236-244 , April 2010

Intensity-modulated Radiotherapy Allows Escalation of the Radiation Dose to the Pelvic Lymph Nodes in Patients with Locally Advanced Prostate Cancer: Preliminary Results of a Phase I Dose Escalation Study

  • T. Guerrero Urbano

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • Present address: St Thomas' Hospital, London, UK.
    • ,
  • V. Khoo

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • J. Staffurth

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • Present address: Department of Clinical Oncology, Velindre Hospital, Cardiff, UK.
    • ,
  • A. Norman

      Affiliations

    • Computing Department, Royal Marsden Hospital, Sutton, UK
    • ,
  • F. Buffa

      Affiliations

    • Gray Cancer Institute, University of Oxford, UK
    • ,
  • A. Jackson

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • Present address: Academic Department of Radiation Oncology, University of Manchester, UK.
    • ,
  • E. Adams

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • Present address: Royal Surrey Hospital, Guildford, UK.
    • ,
  • V. Hansen

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • C. Clark

      Affiliations

    • Joint Department of Physics, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • E. Miles

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • Present address: Mount Vernon Hospital, Northwood, UK.
    • ,
  • H. McNair

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • C. Nutting

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • C. Parker

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • R. Eeles

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • R. Huddart

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • A. Horwich

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • ,
  • D.P. Dearnaley

      Affiliations

    • Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    • Corresponding Author InformationAuthor for correspondence: D.P. Dearnaley, Academic Department of Clinical Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel: +44-20-8661-3271; Fax: +44-20-8643-8809.

Received 2 October 2009 ,Revised 14 December 2009 ,Accepted 5 January 2010.

References 

  1. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609–615
  2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106
  3. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–2527
  4. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  5. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  6. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308
  7. Pan CC, Kim KY, Taylor JM, et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53:1139–1145
  8. Seaward SA, Weinberg V, Lewis P, et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:1055–1062
  9. Ploysongsang SS, Aron BS, Shehata WM. Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate?. Urology. 1992;40:18–26
  10. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–655
  11. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–5373
  12. Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys. 1986;12:1565–1573
  13. Letschert JG, Lebesque JV, de Boer RW, et al. Dose-volume correlation in radiation-related late small-bowel complications: a clinical study. Radiother Oncol. 1990;18:307–320
  14. Nutting C, Convery D, Cosgrove V, et al. Reduction in small and large bowel irradiation using an optimised intensity-modulated pelvic radiotherapy technique (IMRT) in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48(3):649–656
  15. Roach M, Marquez C, You H-S, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33–37
  16. Staffurth J, Adams E, Breen S, et al. Target volume definition for intensity modulated whole pelvic radiotherapy (IMWPRT), ASCO Prostate Cancer Symposium. Orlando, Florida 17/18 February 2005, abstract no. 185.
  17. Adams EJ, Convery DJ, Cosgrove VP, et al. Clinical implementation of dynamic and step and shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol. 2004;70:1–10
  18. Clark CH, Mbuata CD, Meehan CA, et al. IMRT clinical implementation: prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. J Appl Clin Med Phys. 2002;3:273–284
  19. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953–962
  20. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  21. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48:635–642
  22. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002;52:1330–1337
  23. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  24. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498
  25. Capirci C, Polico C, Mandoliti G. Dislocation of small bowel volume within box pelvic treatment fields, using new ‘up down table’ device. Int J Radiat Oncol Biol Phys. 2001;51:465–473
  26. Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201–207
  27. Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002;52:176–183
  28. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1998;41:83–92
  29. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  30. Dearnaley D, Sumo G, Syndikus I, et al. Initial toxicity results of the phase III conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP) trial (ISRCTN97182923), ASCO Genitourinary Cancers Symposium. Orlando, Florida, USA, 2009.
  31. Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer—the CHHiP trial. Clin Oncol (R Coll Radiol). 2008;20:12–14

PII: S0936-6555(10)00036-1

doi: 10.1016/j.clon.2010.01.005

Clinical Oncology
Volume 22, Issue 3 , Pages 236-244 , April 2010

Article Tools

* Image Usage & Resolution